Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study

N. Kwon (Brentford, Middlesex, United Kingdom), K. Gemzoe (Stockley Park, Uxbridge, Middlesex, United Kingdom), S. Worsley (Stockley Park, Uxbridge, Middlesex, United Kingdom), N. Gunsoy (Stockley Park, Uxbridge, Middlesex, United Kingdom), S. Joksaite (Stockley Park, Uxbridge, Middlesex, United Kingdom), M. Van Dyke (Upper Providence, PA, United States of America), C. Bettinson (Stockley Park, Uxbridge, Middlesex, United Kingdom), F. Albers (Research Triangle Park, NC, United States of America)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1036
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Kwon (Brentford, Middlesex, United Kingdom), K. Gemzoe (Stockley Park, Uxbridge, Middlesex, United Kingdom), S. Worsley (Stockley Park, Uxbridge, Middlesex, United Kingdom), N. Gunsoy (Stockley Park, Uxbridge, Middlesex, United Kingdom), S. Joksaite (Stockley Park, Uxbridge, Middlesex, United Kingdom), M. Van Dyke (Upper Providence, PA, United States of America), C. Bettinson (Stockley Park, Uxbridge, Middlesex, United Kingdom), F. Albers (Research Triangle Park, NC, United States of America). Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study. 1036

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: